• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » CorMatrix launches FDA IDE Cor Tricuspid ECM cardiac valve trial

CorMatrix launches FDA IDE Cor Tricuspid ECM cardiac valve trial

February 21, 2019 By Fink Densford

CorMatrix Cardiovascular

CorMatrix Cardiovascular said today that it launched a trial of its Cor Tricuspid ECM cardiac valve intended for treating adults with endocarditis and pediatric patients with congenital heart valve disease, adding that the first patient in the trial has already been treated.

The first procedure in the trial took place at the Francicscan Health Heart Center by a team led by Dr. Marc Gerdisch, Atlanta-based CorMatrix said. The patient, who was suffering from endocarditis, has returned home and is recovering well, the company added.

“This first FDA study enrollment is a substantial step toward patients avoiding synthetic or animal tissue replacement valves, by having the opportunity to regrow their own tissue. We have been using CorMatrix for eight years with exceptional success in reconstructing complex structures of the heart and blood vessels. Given the remarkable adaptability and regenerative properties of CorMatrix, this new valve structure will have a dramatic effect on surgery for tricuspid valve pathology, especially for younger patients. Furthermore, it serves as a platform for engineering other heart valves,” Dr. Gerdisch said in a prepared statement.

CorMatrix touts its Cor Tricuspid ECM cardiac valve as the first cardiac valve of its kind to be composed of an extracellular matrix, and said that its CorMatrix ECM material has been used in more than 220,000 cardiac implants to date.

“This important step for our patients and CorMatrix, to create a valve that will mimic in all respects a normal valve is no easy task, but the technology and our ability to harness the regenerative potential continues to improve,” chief medical and scientific officer Dr. Robert Matheny said in a prepared staetment.

“The Cor Tricuspid ECM valve is the first seamless ECM cardiac valve approved by the FDA for an IDE safety and feasibility clinical trial for adult and pediatric patient applications. We are very pleased to be working with Dr. Gerdisch and through his leadership, with the team at Franciscan Health Heart Center on this important study. The Cor Tricuspid ECM valve joins a rapidly developing CorMatrix pipeline of next generation ECM products and patient solutions,” prez & CEO Edgar Rey said in a press release.

Last month, CorMatrix said that it won FDA investigational device exemption approval to launch an early feasibility study of the Cor Tricuspid ECM cardiac valve.

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured, Replacement Heart Valves Tagged With: CorMatrix Cardiovascular Inc.

More recent news

  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy